logo
European Perspectives
Circulation: Clinical Summaries
Birth Weight and Atrial Fibrillation
A Master of Versatility to the Heart's Rescue
Birth Weight Is a Significant Risk Factor for Incident Atrial Fibrillation
Aldehyde Dehydrogenase Activation Prevents Reperfusion Arrhythmias by Inhibiting Local Renin Release From Cardiac Mast Cells
Complex Interactions Between the Sinoatrial Node and Atrium During Reentrant Arrhythmias in the Canine Heart
Exercise Capacity and Mortality in Older Men
Three-Dimensional and Molecular Analysis of the Venous Pole of the Developing Human Heart
Deficiency of Antigen-Presenting Cell Invariant Chain Reduces Atherosclerosis in Mice
Early Atherosclerosis Exhibits an Enhanced Procoagulant State
Atrioventricular Nodal Reentrant Tachycardia
ACCORD(ing) to a Trialist
Effects of Intensive Glucose Lowering in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Effects of Intensive Blood Pressure Control in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Superior Vena Cava Occlusion by Cardiovascular Magnetic Resonance
Giant Left Circumflex Coronary Fistula to the Right Atrium
Letter by Serebruany Regarding Article, “Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38”
Response to Letter Regarding Article, “Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38”
Correction
Correction
Correction